Labcorp Holdings Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Labcorp Holdings Inc 's ROA in the second quarter of 2026?
Labcorp Holdings Inc achieved a return on average assets (ROA) of 5.4 % in its second quarter of 2026, which is below Labcorp Holdings Inc 's average return on assets, which stands at 7.18%.

ROA has improved compared to 5.09% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 148 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 1151, from total ROA ranking in the first quarter of 2026 at 1403.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	1.45 %	9.25 %	0.9 %	-0.99 %	9.4 %
Y / Y Net Income Change	25.51 %	30.52 %	14.83 %	54.19 %	15.9 %
Net Income (TTM) in million	1,004	943	878	856	765
Return On Assets (TTM)	5.4 %	5.09 %	4.84 %	4.74 %	4.22 %
LH's Total Ranking	# 1151	# 1403	# 1231	# 1316	# 1348
Total Assets (TTM) in million	18,322	19,234	18,547	18,264	18,061
Seq. Total Assets Change	-4.74 %	3.7 %	1.55 %	1.12 %	2.59 %
Seq. Net Income Change	7.59 %	68.59 %	-36.94 %	9.74 %	11.88 %

LH's 5 Years Annual ROA >> Back to LH Management Effectiveness >> Compare LH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 9
Sector	# 149
Overall	# 1098

Return On Assets Statistics
High	Average	Low
14.47 %	7.18 %	-1.22 %
(Jun 30 2021)		(Mar 31 2020)

Financial Statements
Labcorp Holdings Inc 's Assets	$ 18,322 million	LH's Balance sheet
Labcorp Holdings Inc 's Income	$ 299 million	Quarterly LH's Income Statement
LH's Income by Division		See LH's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	0.9 %	9.89 %	-17.01 %	0.42 %	11.22 %
Total Assets in million	18,547	18,382	16,728	20,157	20,072
Y / Y Net Income Change	17.48 %	78.22 %	-67.27 %	-17.75 %	88.75 %
Net Income in million	878	747	419	1,281	1,557
Annual Return On Assets	4.73 %	4.06 %	2.51 %	6.35 %	7.76 %

LH's 5 Years Annual ROA >> Back to LH Management Effectiveness >> Compare LH ROA to its Competitors

Comment on LH's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 4.73 % compared to prior year, due to annual net income growth of 17.48 % to $877.70 million, while value of Labcorp Holdings Inc 's overall assets grew just by 0.9 % to $18,546.60 million, compared to $18,546.60 a year before.

More Return On Assets Ratios
LH's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LH's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LH's Competitors
Subscribers only: Roa for Labcorp Holdings Inc 's Suppliers
Subscribers only: Return On Assets for LH's Customers

You may also want to know
LH's Roi	LH's Inventory Turnover Ratio	LH's Growth Rates	LH's Dividend Comparisons
	LH's Profitability Ratios	LH's Asset Turnover Ratio	LH's Dividend Growth
LH's Roe	LH's Valuation Ratios	LH's Financial Strength Ratios	LH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %
Strata Critical Medical Inc	12.18 %
Insulet Corporation	12.13 %
Lantheus Holdings Inc	11.89 %
Ligand Pharmaceuticals Incorporated	11.68 %
Theravance Biopharma inc	11.68 %
Carlisle Companies Incorporated	11.62 %
Encompass Health Corporation	11.60 %
Protagonist Therapeutics inc	11.02 %
Agilent Technologies inc	10.97 %
Prestige Consumer Healthcare Inc	10.90 %
Lemaitre Vascular Inc	10.90 %
Ufp Technologies Inc	10.85 %

Date modified: 2026-09-12T18:38:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.